DE69211258T2 - (R)-3-Methoxy-4-(1-Methyl)-5-(2-Methyl-4,4,4-Trifluorbutylcarbamoyl)Indol-3-Ylmethyl)-N-(2-Methylsulfonyl)-Benzamid in kristalliner Form - Google Patents

(R)-3-Methoxy-4-(1-Methyl)-5-(2-Methyl-4,4,4-Trifluorbutylcarbamoyl)Indol-3-Ylmethyl)-N-(2-Methylsulfonyl)-Benzamid in kristalliner Form

Info

Publication number
DE69211258T2
DE69211258T2 DE69211258T DE69211258T DE69211258T2 DE 69211258 T2 DE69211258 T2 DE 69211258T2 DE 69211258 T DE69211258 T DE 69211258T DE 69211258 T DE69211258 T DE 69211258T DE 69211258 T2 DE69211258 T2 DE 69211258T2
Authority
DE
Germany
Prior art keywords
methyl
ylmethyl
methoxy
benzamide
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69211258T
Other languages
German (de)
English (en)
Other versions
DE69211258D1 (de
Inventor
Murray Watson Cuthbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of DE69211258D1 publication Critical patent/DE69211258D1/de
Publication of DE69211258T2 publication Critical patent/DE69211258T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE69211258T 1991-09-05 1992-09-01 (R)-3-Methoxy-4-(1-Methyl)-5-(2-Methyl-4,4,4-Trifluorbutylcarbamoyl)Indol-3-Ylmethyl)-N-(2-Methylsulfonyl)-Benzamid in kristalliner Form Expired - Lifetime DE69211258T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919119001A GB9119001D0 (en) 1991-09-05 1991-09-05 Pharmaceutical agents

Publications (2)

Publication Number Publication Date
DE69211258D1 DE69211258D1 (de) 1996-07-11
DE69211258T2 true DE69211258T2 (de) 1996-10-02

Family

ID=10700953

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69211258T Expired - Lifetime DE69211258T2 (de) 1991-09-05 1992-09-01 (R)-3-Methoxy-4-(1-Methyl)-5-(2-Methyl-4,4,4-Trifluorbutylcarbamoyl)Indol-3-Ylmethyl)-N-(2-Methylsulfonyl)-Benzamid in kristalliner Form

Country Status (21)

Country Link
US (2) US5352694A (enExample)
EP (1) EP0531078B1 (enExample)
JP (1) JP2914414B2 (enExample)
KR (1) KR100254710B1 (enExample)
AT (1) ATE138910T1 (enExample)
AU (1) AU646587B2 (enExample)
CA (1) CA2076722A1 (enExample)
CZ (1) CZ281999B6 (enExample)
DE (1) DE69211258T2 (enExample)
DK (1) DK0531078T3 (enExample)
FI (1) FI102372B (enExample)
GB (2) GB9119001D0 (enExample)
HK (1) HK18297A (enExample)
HU (2) HU213410B (enExample)
IL (1) IL102856A (enExample)
NO (1) NO178370C (enExample)
NZ (1) NZ244016A (enExample)
RU (1) RU2095348C1 (enExample)
SK (1) SK267092A3 (enExample)
TW (1) TW302359B (enExample)
ZA (1) ZA926374B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958780A (en) * 1997-06-30 1999-09-28 Boston Advanced Technologies, Inc. Method for marking and identifying liquids
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
US6149914A (en) * 1999-07-12 2000-11-21 Patel; Jitendra Rambhai Asthma treatment
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
CN102847155B (zh) 2004-07-14 2014-04-16 炎症研究中心有限公司 抑制肿瘤转移的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524152A (en) * 1982-12-30 1985-06-18 Pennwalt Corporation 1-Cyano-3-(fluoroalkyl)guanidines for lowering blood pressure
GB8623429D0 (en) * 1985-10-17 1986-11-05 Ici America Inc Carboximide derivatives
MY103259A (en) * 1987-04-15 1993-05-29 Ici America Inc Aliphatic carboxamides
GB8906032D0 (en) * 1988-04-14 1989-04-26 Ici America Inc Hetera-aliphatic carboxamides
GB8927981D0 (en) * 1989-12-11 1990-02-14 Ici Plc Carbamoyl derivative
GB9026427D0 (en) * 1990-12-05 1991-01-23 Ici Plc Chemical process
GB9026425D0 (en) * 1990-12-05 1991-01-23 Ici Plc Process
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation

Also Published As

Publication number Publication date
HK18297A (en) 1997-02-13
DE69211258D1 (de) 1996-07-11
IL102856A (en) 1996-12-05
ZA926374B (en) 1993-03-05
AU646587B2 (en) 1994-02-24
HUT69696A (en) 1995-09-28
CZ267092A3 (en) 1993-03-17
EP0531078B1 (en) 1996-06-05
EP0531078A1 (en) 1993-03-10
IL102856A0 (en) 1993-01-31
DK0531078T3 (da) 1996-10-14
FI102372B1 (fi) 1998-11-30
GB9216774D0 (en) 1992-09-23
NO923467D0 (no) 1992-09-04
US5466826A (en) 1995-11-14
KR930005976A (ko) 1993-04-20
SK279657B6 (sk) 1999-02-11
FI102372B (fi) 1998-11-30
CZ281999B6 (cs) 1997-04-16
ATE138910T1 (de) 1996-06-15
HU210879A9 (en) 1995-09-28
HU213410B (en) 1997-06-30
RU2095348C1 (ru) 1997-11-10
TW302359B (enExample) 1997-04-11
KR100254710B1 (ko) 2000-05-01
FI923869L (fi) 1993-03-06
NO923467L (no) 1993-03-08
NO178370B (no) 1995-12-04
JP2914414B2 (ja) 1999-06-28
GB9119001D0 (en) 1991-10-23
SK267092A3 (en) 1999-02-11
HU9202660D0 (en) 1992-10-28
AU2101292A (en) 1993-03-11
FI923869A0 (fi) 1992-08-28
US5352694A (en) 1994-10-04
NO178370C (no) 1996-03-13
NZ244016A (en) 1995-01-27
CA2076722A1 (en) 1993-03-06
JPH05194385A (ja) 1993-08-03

Similar Documents

Publication Publication Date Title
DE69615214T2 (de) Substituierte heteroaromatische derivate
DE3855501T2 (de) Chinolin-derivate als antagonisten von leukotrien d 4?
EP0222191B1 (de) 4-Benzyl-1-(2H)-phthalazinon-Derivate
EP2508521A2 (de) Verfahren zur Herstellung von Aminocrotonylverbindungen
DE69112099T2 (de) Kristallinisches Salz von 4-(Di-n-propyl)amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz[cd]indol.
DE60008921T2 (de) Kristalline form von (s)-2-ethoxy-3-4-(2-4-methansulfonyloxyphenyl-ethoxy)phenyl]propansäure
DE202004021379U1 (de) Kristalline Formen von Pitivastatin Calcium
DE69510999T2 (de) Terazosinmonohydrochlorid und Verfahren und Zwischenprodukte für seine Herstellung
DE69211258T2 (de) (R)-3-Methoxy-4-(1-Methyl)-5-(2-Methyl-4,4,4-Trifluorbutylcarbamoyl)Indol-3-Ylmethyl)-N-(2-Methylsulfonyl)-Benzamid in kristalliner Form
DE3586411T2 (de) Dopamin-antagoniste.
DE69032083T2 (de) Carbamoylderivate
EP0539329A1 (de) Acetylen-Verbindungen, verwendbar als Leukotrien-Antagonisten
DE102007032612A1 (de) Polymorphe Formen von Flupirtinmaleat
DE69715196T2 (de) Modifizierte form des hydrochlorids der r(-)-n-(4,4-di(-3-methylthien-2-yl)but-3-enyl)-nipecotinsäure
DE2727342A1 (de) Troponyl-oxalamidsaeure-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
DE3879648T2 (de) N-acyl-n-naphthoylglycine als aldose-reductase-inhibitoren.
DE3879650T2 (de) N-acyl-n-naphthoylglycine als aldose-reductase-inhibitoren.
DE2603417A1 (de) 4-substituierte amino-alpha-aminomethylbenzylalkoholderivate
DE202007011042U1 (de) Polymorphe Formen von Flupirtinmaleat
DE3307172A1 (de) 3-azetidinylethyl-1-phenyl-2-imidazolidinon- derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0725063A1 (de) Chinolin-Derivate
DE3541358A1 (de) Imidazopyridazin-derivate
AT5556U1 (de) Herstellung von säureadditionssalzen des amlodipins aus amlodipinmaleat
DE20116391U1 (de) Amlodipinhemimaleat
AT5463U1 (de) Amlodipinhemimaleat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTRAZENECA UK LTD., LONDON, GB